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Summary: A case of ovarian carcinoma, never previously reported in bear is described. A 37-year-old, nulliparous, female 
Eurasian brown bear hosted at the Falconara Parco Zoo in Italy, showed neurological clinical signs including bilateral blindness 
and signs of hemiparesis involving both limbs of the left side.
A therapy based on fluid, dexamethasone sodium phosphate, ranitidine, ceftriaxone, propentofylline, and a vitamin B complex 
administration was started after the onset of symptoms. After about a week of therapy the bear was able to stand up and walk, 
partially recovered the vision and ate regularly. Despite this initial improvement, three weeks after the clinical onset the bear 
died. At necropsy a large tumourous mass involving the left ovary and spread of tumour metastases to the regional lymph node 
and brain has been found. Based on the typical histological and immunohistochemical features of neoplastic cells, this tumor 
was diagnosed as papillary to solid serous type ovarian carcinoma. Because of the scattered distribution pattern of neoplastic 
nodules, the involvement of the brain and lumbo-aortic lymph node was considered to be metastatic. Only few reports of 
neoplasms in Ursidae can be found in scientific literature and these include lymphosarcoma, osteoma, osteosarcomas, 
chondrosarcoma, squamous cell, biliary, thyroid, mammary, and hepatocellular carcinomas. According to these results, the 
presence of tumor should be considered in bears with neurological signs. 
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Case description
Only few reports of neoplasms in Ursidae can 
be found in scientific literature (1, 2, 3, 4, 5, 6, 
7, 8, 9, 10, 11, 12, 13, 14) and none of this refer 
about ovarian tumor.
A 37-year-old nulliparous female Eurasian 
brown bear (Ursus arctos arctos) 87 Kg in weight, 
hosted at the Falconara Parco Zoo, in Italy, was 
referred because found in lateral recumbency. 
The bear was borne in the Zoo of Verona, Italy, 
and moved in the Falconara Parco Zoo shortly 
after bird. The area that housed the bear was 
made of concrete, divided into different rooms, 
and equipped with windows of armored glass. The 
floor was in concrete and enriched with straw, 
leaves and dead branches. The animal was feed 
once a day with fruits and vegetables and once a 
week beef or chicken meat was administered. No 
other bears were hosted in the zoo and no previous 
health problems were recorded. Deworming were 
performed once a year with ivermectine. 
G. Rossi, F. Laus, A. Piccinini, R. Piccinini, F. Pasquinelli, R. Gambi, E. Paggi, B. Tesei100
The general conditions allowed to approach 
the bear without a dangerous situation occurs. 
In effect, the bear did not react to the approach 
of the people but she tried some slight reaction 
(feeble attempts to bite), when was touched. The 
bear resulted to be slightly dehydrated, appeared 
bilaterally blind at evaluation of the “response 
to the threat” and had signs of hemiparesis 
Parameter Result Reference range
Erythrocytes (106/µl) 3.89 4.17–8.93
Hematocrit (%) 22 36.8–62.7
Hemoglobin (g/dl) 8.7 11.7–59.4
MCV (fl) 56.3 44.1-93.0
MCH (pg) 18.3 15.4-33.5
MCHC (g/dl) 31.5 14.0-63.8
Leukocytes (103/ µl) 38.6 3.9–37.6
         Unsegm. neutrophils (103/ µl) 1.0 <0.01-3.07
         Segm. neutrophils (103/ µl) 31.7 2.55-23.7
         Lymphocytes (103/ µl) 5.1 <0.01-12.4
         Monocytes (103/ µl) 0.3 <0.01-1.59
         Eosinophils (103/ µl) 0.5 <0.01-2.58
         Basophils (103/ µl) 0 <0.01-0.14
Platelets (106/ µl) 399 134–719
Total protein (g/dl) 9.1 5.7–8.8
Albumin (g/dl) 3.3 2.7–5.4
Calcium (mg/dl) 8.9 6.6–11.5
Phosphorus (mg/dl) 5.0 3.2–9.1
Sodium (mEq/l) 133 123–150
Potassium (mEq/l) 4.8 3.6–6.1
Chloride (mEq/l) 100 94–112
Creatinine (mg/dl) 1.7 0.5–3.9
Urea nitrogen (mg/dl) 42 4–43
Cholesterol (mg/dl) 211 172–1030
Total bilirubin (mg/dl) 0.5 0.0–1.4
Direct bilirubin (mg/dl) 0.1 0.0–0.1
ALT (IU/l) 58 10–101
AST (IU/l) 158 25–203
ALP (IU/l) 111 4–210
GGT (IU/l) 432 16–176
Table 1: Results of the hemato-biochemical analysis. Reference ranges are from Ramsay 2003 (15), except for 
leukocytes, white subcellular population (16) and GGT (17)
involving both limbs of the left side. Anyway, 
deep and superficial sensitivities were preserved. 
Widespread tremors and nystagmus were also 
present. The bear appeared conscious and was 
able to eat. A venous sample of blood was collected 
from the jugular vein to analyse the hematologic 
parameters reported in table 1.
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Number of erythrocytes, haematocrit and 
haemoglobin resulted to be decreased causing 
a moderate status of anemia. The number of 
leukocytes was increased with most of them 
represented by segmented neutrophils. Values for 
total protein were slightly increased while GGT 
(gamma-glutamyl transpeptidase) resulted to 
have a fourfold increased activity.
Based on the clinical suspicious of central 
nervous system damage, a therapy including 
fluid administration (ringer lactate only the first 
day), dexamethasone sodium phosphate (4 mg/
Kg, IM, BID the first day and 2 mg/Kg IM, SID 
in the following days), ranitidine (6 mg/Kg PO 
BID; Ranitidina TEVA®, Teva Pharma Italy), 
ceftriaxone (1.5 g, IM, SID; ceftriaxone hexal®, 
Hexal Spa Italy), propentofylline (3 mg/Kg, PO, 
BID; Karsivan®, Intervet Italia Srl), and a vitamin 
B complex PO, SID (Stimulfos®, Teknopharma 
S.p.a.) has been started. Drugs to be given 
parenterally, were administered by dart using a 
blow pipe; PO therapy was administer with food. 
After about a week of therapy the bear was able to 
stand up and walk, partially recovered the vision 
and ate regularly. Nevertheless, three weeks after 
the clinical onset, she went back in decubitus and 
died after 12 hours.
Necropsy revealed an irregular aspect of left 
ovary, and old clots were noted throughout the 
pelvis. The right ovary appeared normal. On gross 
examination, a 20×15×8 centimeter and 435 g in 
weight left ovarian mass was evident. Grossly, 
the external surface was intact and smooth, and 
the cut surface was gray to yellow, predominantly 
solid and lobulated, with a few small areas of 
cystic change and hemorrhage.
A 2.5 cm-sized nodule occupying the lombo-
aortic lymph nodes was also observed. Additionally 
brain metastases were noted, characterized by 
multiple lesions, typically at grey white junction, 
profuse perilesional edema, and relatively smooth 
margin. 
Intimal calcification of the aortic arch and 
scattered petechiae on the mucous membrane of 
the urinary bladder were also observed. 
Tissue samples from tumors and all organs 
were fixed in 10% neutrally-buffered formalin (pH 
7.4), processed for paraffin embedding, sectioned 
at 4 μm and stained with haematoxylin and eosin 
(H&E) and used also for immunohistochemical 
characterization. On the histological examination, 
the ovarian tumor was composed of epithelioid to 
spindle-shaped neoplastic cells that were arranged 
in closely packed hollow or solid tubules with a 
fibrous stroma, resulting in a lobular pattern. 
Diffuse solid areas, microcystic pattern with 
eosinophilic secretion, and focal characteristic 
sieve-like structure were also noticed (Fig. 1). 
The tumor cells showed mild nuclear atypia and 
frequent mitotic figures. Nuclear pleomorphism 
and tumor necrosis was also found. Histology 
of brain metastases revealed a sharp interface 
between brain parenchyma and metastatic tumor. 
The neoplasm had areas of follicular architecture 
and areas of solid nests (Fig. 1), with tumor nuclei 
that were round to oval in shape with prominent 
nucleoli and finely granular chromatin. The 
neoplastic cells had abundant eosinophilic 
cytoplasm and mild pleomorphism. Some features 
of papillary carcinoma were occasionally observed. 
The tumor was intermixed with areas of fibrosis 
with hemosiderin deposition and calcification. 
Focal necrosis and perivascular macrophages 
were also noted. The adjacent brain parenchyma 
contained hemosiderin deposits, vascular sclerosis, 
and reactive astrocytes. Finally, microscopy of 
neoplastic nodules in the lymph nodes showed a 
similar histological pattern, with neoplastic cells 
being arranged in diffusely proliferating sheet-like 
cellular nests. Neoplastic cells were separated by 
variable amounts of fibrous stroma, but they were 
invasive to the stroma and lymphatic vessels. In 
all these three sites of neoplastic development, the 
neoplastic cells were largely polygonal with round 
to oval-shaped nuclei and abundant eosinophilic 
cytoplasm and prominent nucleoli with indistinct 
cellular borders sometimes forming rosettes, 
papillae, and duct-like structures; mitotic figures 
were observed frequently. In the lombo-aortic 
lymph nodes, the lymphoid tissue was mostly 
replaced by neoplastic cells forming a large tumor 
mass. In the brain, a scattered distribution of 
neoplastic cell aggregation of various sizes was 
evident, as well as larger discrete nodules.
Sections from neoplastic tissues of the 
ovary, brain, and lombo-aortic lymph node were 
immunohistochemically stained by the avidin-
biotin-peroxidase complex (ABC) procedure 
(Vectastain Elite ABC Kit; Vector Laboratories, 
Burlingame, CA, U.S.A.) and examined 
microscopically. Details of the specific primary 
antibodies used and the staining results for the 
neoplastic tissues are summarized in Table 2.
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Figure 1: Low-power view of ovarian 
neoplastic tissue, characterized by 
epithelioid to spindle-shaped neoplastic 
cells that were arranged in closely 
packed hollow or solid tubules with 
a fibrous stroma (arrowhead); right 
lower insert: characteristic microcystic 
(sievelike) structure with eosinophilic 
secretion (arrow), interspersed in a 
diffuse solid area. (H&E, Bar = 250µm; 
insert = 100µm)
Primary antibody Antibody clone Dilution Antigen retrieval Results
Vimentin V9 1:30 none +/-
AE1/AE3 AE1 and AE3 1:50 HMAR +++
EMA E29 1:50 HMAR +
CA 125 OC 125 1:25 HMAR +
CEA policlonal 1:400 HMAR -
Calretinin a) policlonal 1:100 HMAR ++
WT1 b) policlonal 1:100 HMAR +
Table 2: Panel of antibodies utilized for tumour characterization
a) made by ZYMED; b) made by LifeSpan Bioscience, Inc., c)HMAR = Heat Mediated Antigen Retrieval
Deparaffinized sections were blocked for 
endogenous peroxidase in 0.3% H2O2 with 
methanol for 30 min. Incubation of sections 
with the primary antibody was performed at 
4°C for 16 h, followed by incubation with the 
biotinylated secondary antibody for 30 min, and 
with avidin peroxidase conjugate for 30 min at 
room temperature. Sections were developed in 
0.05% 3,3’-diaminobenzidine/H2O2 solution. As 
positive control for each immunoreactivity, an 
ovary serous carcinoma, and a colonic carcinoma 
belonging to dog were employed. Additionally, 
a normal ovary and brain tissues from a brown 
bear (archive material) were also used. Samples 
from canine serous ovarian carcinoma were 
used for confirmation of the immunoreactivity 
for epithelial membrane antigen (EMA), Wilms 
Tumor 1 antigen (WT-1), and Cancer Antigen 125 
(CA125). Neoplastic colonic tissue was used for 
confirmation of the immunoreactivity for Carcino-
Embryonic Antigen (CEA), and EMA. Finally 
normal brown bear tissue from ovary and brain 
were used as positive control for cytokeratins and 
vimentin stain.
The utilized antibodies were concentrated 
antibodies made by DAKOCytomation, Denmark, 
ZYMED Laboratories Inc., San Francisco (for 
Calretinin polyclonal antibody), and LifeSpan 
Bioscience, Inc. (for WT-1 polyclonal antibody, LS-
B4578). In order to confirm immunohistochemically 
the diagnosis of carcinoma of the ovary, all the 
specimens were initially marked with vimentin 
to control the primary processing of the analyzed 
case. First we chose a panel of antibodies to help 
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Figure 2: A) Diffuse and strong 
positivity of tumor cells, especially 
pseudo-cysts forming cells, for A1-
A3 citockeratins. B) Diffuse positivity 
restricted to pseudo-cysts forming 
cells for EMA. C) Calretinin diffuse 
and light to moderate positivity of all 
tumoral cells. D) Similar pattern of 
diffuse and light positivity, with the 
exception of the pseudo-cysts forming 
cells, for CA125 antigen. E) Substantial 
negativity of all neoplastic cells for CEA 
antigen. Note in right lower insert the 
strong and diffuse nuclear positivity of 
the neoplastic cells for WT-1 antigen. 
F) Strong positivity of brain metastasis 
for citockeratins A1-A3. Note the 
intense inflammatory reaction and 
edema around the neoplastic tissue. 
(IHC stain. Bar = 100 µm; insert and 
panel F = 250 µm)
establish the epithelial origin of the tumour. 
Thus, we opted for cytokeratin AE1/AE3, and 
EMA antibodies. Since there is no specific marker 
to indicate the ovarian origin of the tumor, the 
differentiation of the studied tumor from possible 
ovarian metastasis was realized through several 
associated immunohistochemical reactions. Thus, 
the anti-calretinin antibody was used in attempt 
to help, together with the CA125, CEA, and WT-1 
antibodies, to eliminate a mesothelioma belonging 
to the peritoneal cavity. The CEA staining allowed 
the separation of this tumor from ovarian 
metastasis originating in the gastrointestinal 
tract. Finally, WT-1 staining was used in attempt 
to speculate the serous, non mucinic origin of 
the ovarian neoplasia. The immunostaining 
intensity was evaluated using a four-degree-
system in accordance with the model of Wauters, 
1995. Immunohistochemistry stain was notable 
and intense for pan-cytokeratin (Fig. 2A, and F), 
moderate and diffuse for calretinin (Fig. 2C), light 
to moderate and “periacinar” for EMA (Fig. 2B), 
and focal and nuclear for WT-1 (Fig. 2E, insert). 
Not unexpected in such a high grade carcinoma, 
vimentin staining was positive in a minority of 
epithelial cells. Calretinin staining was focally 
strongly positive, also in brain and lymph node 
metastases. Additionally, neoplastic cells showed 
a moderate and focal stain for CA125 (Fig. 2D), 
resulting consistently negative for CEA antigen (Fig. 
2E). In all the neoplastic samples (primary tumor 
and metastases) the inconspicuous and myxoid 
stroma resulted strongly positive for vimentin, as 
expected.. On the basis of the tumor architecture, 
and the immunohistochemical profile, the tumor 
was classified, according WHO guidelines (18), as 
ovarian carcinoma serous type, papillary to solid.
According to WHO classification, ovarian 
cancers are classified in three categories: epithelial 
tumors (arise from cells that line or cover the 
ovaries); germ cell tumors (originate from cells 
that are destined to form eggs within the ovaries); 
and sex cord-stromal cell tumors (begin in the 
connective cells that hold the ovaries together 
and produce female hormones) (18). Common 
epithelial tumors begin in the surface epithelium of 
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the ovaries are divided into serous, endometrioid, 
mucinous, and clear cell tumors subtypes. 
Unfortunately, extraovarian mesotheliomas, 
peritoneal carcinoma, or ovarian metastatic 
carcinomas belonging to gastrointestinal tract, 
represent some tumors that are adjacent to 
ovarian tissues and may be viewed as ovarian 
cancer, complicating the histological diagnosis.
In our case, the immunohistochemical 
analysis of primary tumor and metastases 
revealed a characteristic profile of the 
neoplasia. Anticalretinin antibody was used 
(presently considered to be the best marker for 
mesotheliomas) together with cytokeratins, EMA 
and CA125 antibodies (epithelial cells markers). 
The immunostaining for cytokeratin AE1/AE3 
was of great importance in the determination 
of the epithelial origin of the tumour since, for 
this marker, primary neoplasia and metastases 
were positive at the level of tumour cells (Fig. 
2A, and F). The positivity of the ovarian surface 
epithelium for calretinin, was very helpful since 
it represented the positive internal control. In our 
case, the light cytoplasmic and diffuse pattern of 
calretinin positivity in neoplastic cells, suggested 
an ovarian surface epithelial tumor (Fig. 2C). The 
immunostaining was frequently diffuse and the 
intensity of the reaction was strong positive. The 
EMA expression of neoplastic cells is tipical for 
poorly differentiated ovarian carcinomas (19), and 
this antibody emphasized acinar differentiation 
(Fig. 2B), often where it was not easily observed in 
haematoxylin and eosin preparations (20). Even 
if CA125 is not a specific marker of the ovarian 
origin of the tumor, some studies have shown a 
CA125 heterogeneous positivity in specimens 
of ovarian serous carcinomas (21). This type of 
heterogeneous staining, observed also in our 
case, was in favor of the ovarian origin (Fig. 2D). 
Since tumors with gastrointestinal origin are 
intense and diffusely positive for CEA (20), the 
negativity of this brown beer tumor supported the 
ovarian origin (Fig. 2E). Besides, when present, 
CEA expression is indicative of the mucinous type 
differentiation in ovarian tumors which are, at the 
same time, negative for CA125 (21).
Then, immunohistochemistry completed 
the present study of metastasizing ovarian 
tumor, allowing its separation from peritoneal 
mesotheliomas with ovarian extension and from 
ovarian metastasis of a primary gastrointestinal 
carcinoma.
The brain, along with the bone, liver, and lung, 
is one of the most common sites of metastasis 
of ovarian carcinomas. Weakness, depression, 
anorexia, unstable gait, alteration of the vision, 
slurred speech, dizziness or vertigo, head tilting 
are some of the neurological symptoms reported 
in human and animals with brain metastases (22, 
23, 24) but, of course, they depend form the site 
of metastases implantation. Regarding clinical 
pathology, results were not indicative of specific 
diseases: many cancer patients have a mild 
normocytic, non-regenerative anemia associated 
with chronic disease. The increase in serum 
γ-glutamyltransferase was considered to be due to 
hepatic damage, but no metastases were found in 
the liver. Neutrophilia could be due to the reaction 
against the tumors and increasing in total protein 
could have been caused by  slight dehydration. 
In summary, we report here a case of 
malignant metastasizing ovarian tumor in a 
brown beer. Because of typical histological and 
immunohistochemical features of neoplastic 
cells, this tumor was diagnosed as papillary to 
solid serous type ovarian carcinoma. Because of 
the scattered distribution pattern of neoplastic 
nodules, the involvement of the brain and lombo-
aortic lymph node was considered to be metastatic. 
According to these results, the presence of tumor 
should be considered in bears with neurological 
signs.
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METASTAZIRAJOČI KARCINOM JAJČNIKA PRI EVROAZIJSKEM RJAVEM MEDVEDU 
(Ursus arctos arctos): KLINIČNI PRIMER
Povzetek: V članku je opisan primer karcinoma jajčnika pri rjavemu medvedu. Evroazijska rjava medvedka, stara 37 let, brez 
mladičev, iz živalskega vrta Falconara v Italiji, je kazala klinične znake nevroloških motenj, in sicer obojestransko slepoto ter 
znake delne levostranske pareze obeh okončin.
Po opaženih kliničnih znakih je bila medvedka zdravljena z deksametazonom, ranitidinom, ceftriaksonom, propentofilinom, 
vitamini kompleksa B in dodajanjem tekočine. Približno po enem tednu so znaki pareze popustili, tako da je medvedka znova 
lahko hodila, delno se ji je povrnil vid in pričela je jesti. Kljub temu začetnemu kliničnemu izboljšanju je medvedka poginila tri 
tedne po pojavu bolezenskih znakov. Med raztelesbo smo našli močno povečan in tumorozno spremenjen levi jajčnik ter 
metastaze v regionalnih bezgavkah in možganih. Glede na značilno histološko sliko in imunohistokemične značilnosti tumorskih 
celic smo tumor diagnosticirali kot papilarni do solidni serozni tip karcinoma jajčnika. Zaradi razpršenega vzorca razporeditve 
žarišč tumorskih celic v možganih ter v ledveno-aortnih bezgavkah smo le-ta opredelili kot metastaze. V literaturi je opisanih le 
nekaj primerov tumorjev pri različnih vrstah medvedov (Ursidae), poročajo o primerih limfosarkoma, osteoma, osteosarkoma, 
hondrosarkoma, ploščatoceličnega karcinoma ter karcinoma žolčevodov, ščitnice, mlečne žleze in jetrnih celic. Glede na naše 
rezultate je potrebno pri medvedih z nevrološkimi kliničnimi znaki pri diferencialni diagnostiki pomisliti tudi na tumorje.
Kljuène beside: možgani; rjavi medved; metastaze; jajčnik; tumor
